UBXN11 and neoplasm: Our study not only highlights DYRK3 as a tumor-promoting oncogene in SOC but also elucidates its potential as a therapeutic target by demonstrating the inhibitory effects of DYRK3 knockdown on cell viability, invasion, and in vivo tumor growth.